10 citations
,
February 2019 in “The New England Journal of Medicine” Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.
5 citations
,
January 2025 in “Cancers” Improving treatment plans can reduce hair loss and improve life quality for ovarian cancer patients.
2 citations
,
May 2012 in “Annals of Oncology” Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.
2 citations
,
November 2025 in “Cancer Imaging” Ultrasound-based radiomics and radiogenomics can improve ovarian cancer diagnosis and treatment, but need better standardization and AI tools.
March 2024 in “BMC cancer” High levels of ST14 and TMEFF1 proteins in ovarian cancer are linked to worse patient outcomes and may be a new treatment target.
December 2023 in “Frontiers in oncology” Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.
1 citations
,
September 2020 in “Endocrinology, Diabetes & Metabolism Case Reports” The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.
29 citations
,
February 2021 in “Cancers” Ion channels play a key role in ovarian cancer growth and treatment resistance.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
5 citations
,
June 2005 in “Journal of Clinical Oncology” PPX causes much less hair loss than traditional taxanes.
3 citations
,
February 2023 in “Journal of drug delivery science and technology” The new drug carriers show promise for better targeting and treating ovarian cancer.
2 citations
,
February 2025 in “Advanced Healthcare Materials” Perhexiline can effectively target ovarian cancer cells left after treatment.
1 citations
,
January 2022 in “Journal of Cancer Therapy” Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.
13 citations
,
June 2021 in “Carcinogenesis” Certain hair straighteners and dyes may increase ovarian cancer risk, especially in African American/Black women.
106 citations
,
March 2013 in “Nature Communications” A new genetic region, 17q21.31, is linked to higher ovarian cancer risk.
5 citations
,
October 2018 in “Journal of Mind and Medical Sciences” Sentinel lymph node mapping is safe and effective for early-stage ovarian cancer but isn't yet standard practice.
July 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” The study developed a 3D model that closely imitates remaining ovarian cancer after treatment and identified a potential drug targeting resistant cancer cells.
294 citations
,
March 2016 in “European journal of cancer” Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.
18 citations
,
April 2011 in “International Journal of Molecular Medicine” Dihydrotestosterone causes p27 protein breakdown in ovarian and breast cancer cells by binding with SKP2.
January 2017 in “Digital Commons - University of South Florida (University of South Florida)” Hair loss from chemotherapy causes significant distress and affects social roles for ovarian and uterine cancer patients.
28 citations
,
September 2014 in “Journal of Clinical Oncology” Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.
21 citations
,
August 2003 in “Seminars in oncology nursing” Nurses are crucial in managing chemotherapy side effects for ovarian cancer patients to improve their quality of life.
March 2024 in “Frontiers in genetics” Different types of fibroblasts play specific roles in wound healing and cancer, which could help improve treatments.
February 2021 in “Research Square (Research Square)” The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.
93 citations
,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
29 citations
,
August 2007 in “Annals of Oncology” Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
May 2026 in “Pacific Rim International Journal of Nursing Research” This study examined the impact of symptom experiences and management behaviors on the quality of life in 96 women with ovarian cancer undergoing chemotherapy in Thailand. The research found that while participants experienced multiple symptoms, numbness/tingling and fatigue were most common, with neuropathy and fatigue being the most severe. Symptom management was moderately effective, notably improving hair loss and nausea, but not neuropathy. Quality of life was generally rated as good, with symptom experiences significantly affecting it, though management effectiveness did not. Symptom interference was a significant negative predictor of quality of life, explaining 28.6% of its variance. The study highlights the importance of comprehensive symptom assessments and targeted interventions to reduce interference, neuropathy, and fatigue to enhance quality of life.
December 2014 in “Endocrinología y nutrición” The woman's rare combination of diseases suggests an unknown factor may predispose individuals to multiple endocrine diseases.
5 citations
,
January 2024 in “American Journal of Translational Research” Gut bacteria affect female reproductive health and may help diagnose and treat related diseases.